What top creators are saying about 10x Genomics, Inc.(TXG)
A life sciences technology company that designs and manufactures solutions for single-cell genomic analysis.
9 AI-extracted insights from 6 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 3 scored insights about 10x Genomics, Inc..
The Take
Coverage was mixed, leaning bearish: two of three sources floated 10x Genomics (TXG) as a possible short, while one noted its large year-to-date gains without giving an investment thesis.
Bull Case
- Year-to-date gains: TXG was mentioned among stocks with large year-to-date gains, though no return or bullish thesis was specified (Shkreli Planet).
Bear Case
- Possible short candidate: TXG was named as a potential short, without a price target, time horizon, or detailed thesis (The Shkreli Pill).
- Short alternative: TXG was suggested as a possible short alternative to Twist Bioscience, with no catalyst or risk analysis (Martin Shkreli).
Catalysts & Targets
- No specific dates, price targets, or company catalysts were provided.
AI-generated summary. Not investment advice. Learn more.
Top creators covering 10x Genomics, Inc. (TXG)
The 6 sources with the most insights about 10x Genomics, Inc. on Kazuha.
Latest insights about 10x Genomics, Inc. (TXG)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Wednesday, November 4, 2026
Mentioned among stocks with large year-to-date gains, with no specific return or investment thesis provided.
Saturday, October 17, 2026
Mentioned as a possible short candidate, but no price target, time horizon, or detailed short thesis was provided.
Thursday, October 15, 2026
Suggested as a possible short alternative to Twist Bioscience, but without a developed thesis, catalyst, or risk analysis.
Tuesday, October 6, 2026
Mentioned in passing without specific investment analysis or a price target.
Sunday, October 4, 2026
Named as a picks-and-shovels exposure to AI drug discovery, which may increase demand for laboratory validation.
Monday, July 20, 2026
Friday, July 17, 2026
Skeptical outlook ahead of Phase 3 data in August; options market suggests a high probability of trial failure.
Tuesday, July 14, 2026
Thursday, August 28, 2025
A patent from 2011 is now enabling the company to increase the amount of information it can collect by 100-fold, giving it a significant technological advantage and edge in the genomics research market.
Wednesday, November 4, 2026
Mentioned among stocks with large year-to-date gains, with no specific return or investment thesis provided.
Saturday, October 17, 2026
Mentioned as a possible short candidate, but no price target, time horizon, or detailed short thesis was provided.
Thursday, October 15, 2026
Suggested as a possible short alternative to Twist Bioscience, but without a developed thesis, catalyst, or risk analysis.
Tuesday, October 6, 2026
Mentioned in passing without specific investment analysis or a price target.
Sunday, October 4, 2026
Named as a picks-and-shovels exposure to AI drug discovery, which may increase demand for laboratory validation.
Monday, July 20, 2026
Friday, July 17, 2026
Skeptical outlook ahead of Phase 3 data in August; options market suggests a high probability of trial failure.
Tuesday, July 14, 2026
Thursday, August 28, 2025
A patent from 2011 is now enabling the company to increase the amount of information it can collect by 100-fold, giving it a significant technological advantage and edge in the genomics research market.
Discussed alongside 10x Genomics, Inc. (TXG)
Other assets that creators frequently mention in the same content as 10x Genomics, Inc..
Frequently asked
Are top creators bullish or bearish on 10x Genomics, Inc. (TXG) right now?
Mostly bearish. In the last 30 days, 0 insights were bullish, 2 bearish, and 1 neutral about 10x Genomics, Inc. (TXG) across 6 financial sources indexed on Kazuha.
Which podcasters and creators cover 10x Genomics, Inc. (TXG) the most?
The most active sources covering 10x Genomics, Inc. (TXG) on Kazuha are @realmartinshkreli, bubbleboi, @amitinvesting, @theshkrelipill, Joe Rogan. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about 10x Genomics, Inc. (TXG) are on Kazuha?
Kazuha has indexed 9 AI-extracted insights about 10x Genomics, Inc. (TXG) from 6 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside 10x Genomics, Inc. (TXG)?
Creators covering 10x Genomics, Inc. (TXG) most frequently also discuss MU, NVDA, MRNA, AMD, AAPL. See the "Discussed alongside" section above for full asset pages.